Drug Profile
Mdm2-p53 binding protein inhibitor - Boehringer Ingelheim/Priaxon
Alternative Names: Mdm2-p53 antagonist - Boehringer Ingelheim/PriaxonLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Priaxon
- Class Antineoplastics; Small molecules
- Mechanism of Action MDM4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 07 Dec 2022 Phase-I clinical trials in Cancer (unspecified route) (Boehringer Ingelheim pipeline, December 2022)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 24 Jan 2012 Boehringer Ingelheim and Priaxon extend their collaboration and licensing agreement for mdm2/p53 inhibitors